Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study

References

• Willemze R, Jaffe E S, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785
   PubMed Web of Science ®Google Scholar
• Pimpinelli N, Masala G, Santucci M. Primary cutaneous lymphomas in Florence: a population-based study 1986–1995. Ann Oncol 1996; 7: 130–135
   Google Scholar
• Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Cancer 1991; 67: 2311–2326
   PubMed Web of Science ®Google Scholar
• Grange F, Hedelin G, Joly P, et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome: the French study group on cutaneous lymphomas. Blood 1999; 93: 3637–3642
   PubMed Web of Science ®Google Scholar
• Senff N J, Hoefnagel J J, Neelis K J, et al. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 2007; 143: 1520–1526
   PubMed Web of Science ®Google Scholar
• Vermeer M H, Geelen F AMJ, van Haselen C W, et al. Primary cutaneous large B-cell lymphomas of the legs: a distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Arch Dermatol 1996; 132: 1304–1308
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian study group for cutaneous lymphomas. J Clin Oncol 2006; 24: 1376–1382
   PubMed Web of Science ®Google Scholar
• Eich H T, Eich D, Micke O, et al. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma. Int J Radiat Oncol Biol Phys 2003; 55: 899–906
   PubMed Web of Science ®Google Scholar
• Heinzerling L M, Urbanek M, Funk J O, et al. Reduction of tumour burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835–1844
   PubMed Web of Science ®Google Scholar
• Gellrich S, Muche J M, Wilks A, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas – an applicational observation. Br J Dermatol 2005; 153: 167–173
   PubMed Web of Science ®Google Scholar
• Grange F, Bekkenk M W, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19: 3602–3610
   PubMed Web of Science ®Google Scholar
• Wollina U, Hahnfeld S, Kosmehl H. Primary cutaneous marginal center lymphoma complete remission induced by interferon alpha2a. J Cancer Res Clin Oncol 1999; 125: 305–308
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–2642
   PubMed Web of Science ®Google Scholar
• Nourigat C, Badger C C, Bernstein I D. Treatment of lymphoma with radiolabeled antibody: elimination of tumour cells lacking target antigen. J Natl Cancer Inst 1990; 82: 47–50
   PubMed Web of Science ®Google Scholar
• Witzig T E, Gordon L I, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• Witzig T E, Flinn I W, Gordon L I, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Gordon L I, Multani P S, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–4342
   PubMed Web of Science ®Google Scholar
• Gordon L I, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5: 98–101
   PubMedGoogle Scholar
• Cheung M C, Haynes A E, Stevens A, et al. Members of the hematology disease site group of the cancer care ontario program in evidence-based care. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymphoma 2006; 47: 1719–1720
   Web of Science ®Google Scholar
• Witzig T E, Molina A, Gordon L I, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804–1810
   PubMed Web of Science ®Google Scholar
• Schilder R, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004; 19: 478–481
   PubMed Web of Science ®Google Scholar
• van Dongen J J, Langerak A W, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukaemia 2003; 17: 2257–2317
   PubMed Web of Science ®Google Scholar
• Macklis R M, Pohlman P. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists. Int J Radiat Oncol Biol Phys 2006; 66: 833–841
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Estes J, Zasadny K R, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266
   PubMed Web of Science ®Google Scholar
• Witzig T E, White C A, Gordon L I, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263–1270
   PubMed Web of Science ®Google Scholar